Sandbox Reserved 1160
From Proteopedia
(Difference between revisions)
| Line 21: | Line 21: | ||
=== Ionic Locks === | === Ionic Locks === | ||
| - | Another important structural feature of the protein is the series of <scene name='72/721531/Ionic_lock/2'>ionic locks</scene> on the intracellular side of the protein. Interaction between amino acids will form a salt bridge which will stabilize the inactive conformation. The primary ionic lock forms between Glu770, Lys665, and Ser613. A secondary ionic lock occurs between Ser614 and Arg668. The purpose of these ionic locks are analogous to the ionic interactions that stabilize the T state in hemoglobin. In the case of the TMD, when the NAM mavoglurant is bound the ionic lock is formed. This stabilizes the inactive state, where the intracellular loops are stabilized. This will effectively block | + | Another important structural feature of the protein is the series of <scene name='72/721531/Ionic_lock/2'>ionic locks</scene> on the intracellular side of the protein. Interaction between amino acids will form a salt bridge which will stabilize the inactive conformation. The primary ionic lock forms between Glu770, Lys665, and Ser613. A secondary ionic lock occurs between Ser614 and Arg668. The purpose of these ionic locks are analogous to the ionic interactions that stabilize the T state in hemoglobin. In the case of the TMD, when the NAM mavoglurant is bound the ionic lock is formed. This stabilizes the inactive state, where the intracellular loops are stabilized inwards. This will effectively block the crevice that is involved in binding the G-protien. Models have suggested that, even in a glutamate bound state, the mavoglurant bound receptor would be dimerized but incapable of signaling. This helps maintain the readiness of the pathway, while still decreasing signal response. |
== Function and Pathway == | == Function and Pathway == | ||
| Line 28: | Line 28: | ||
== Disease == | == Disease == | ||
=== Fragile X === | === Fragile X === | ||
| + | |||
=== Parkinsons === | === Parkinsons === | ||
== Relevance == | == Relevance == | ||
Revision as of 00:17, 30 March 2016
Human metabotropic glutamate receptor 5 transmembrane domain
| |||||||||||
References
- ↑ 1.0 1.1 Dore AS, Okrasa K, Patel JC, Serrano-Vega M, Bennett K, Cooke RM, Errey JC, Jazayeri A, Khan S, Tehan B, Weir M, Wiggin GR, Marshall FH. Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain. Nature. 2014 Jul 31;511(7511):557-62. doi: 10.1038/nature13396. Epub 2014 Jul 6. PMID:25042998 doi:http://dx.doi.org/10.1038/nature13396
- ↑ 2.0 2.1 2.2 2.3 Wu H, Wang C, Gregory KJ, Han GW, Cho HP, Xia Y, Niswender CM, Katritch V, Meiler J, Cherezov V, Conn PJ, Stevens RC. Structure of a class C GPCR metabotropic glutamate receptor 1 bound to an allosteric modulator. Science. 2014 Apr 4;344(6179):58-64. doi: 10.1126/science.1249489. Epub 2014 Mar , 6. PMID:24603153 doi:http://dx.doi.org/10.1126/science.1249489
